ES2338097T3 - Procedimiento de identificacion selectiva. - Google Patents
Procedimiento de identificacion selectiva. Download PDFInfo
- Publication number
- ES2338097T3 ES2338097T3 ES01930480T ES01930480T ES2338097T3 ES 2338097 T3 ES2338097 T3 ES 2338097T3 ES 01930480 T ES01930480 T ES 01930480T ES 01930480 T ES01930480 T ES 01930480T ES 2338097 T3 ES2338097 T3 ES 2338097T3
- Authority
- ES
- Spain
- Prior art keywords
- target
- ligands
- bound
- white
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 122
- 239000003446 ligand Substances 0.000 claims abstract description 184
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 121
- 238000012216 screening Methods 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 73
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 238000003752 polymerase chain reaction Methods 0.000 description 53
- 230000027455 binding Effects 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108010067902 Peptide Library Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 238000010828 elution Methods 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000003599 detergent Substances 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000013019 agitation Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- -1 buffers and Chemical class 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 231100000640 hair analysis Toxicity 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013024 troubleshooting Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101000688206 Bos taurus Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 231100000948 EpiDerm Skin Irritation Test Toxicity 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004976 chemiluminescence spectroscopy Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Chemical group 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229940101532 meted Drugs 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19725900P | 2000-04-14 | 2000-04-14 | |
| US197259P | 2000-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2338097T3 true ES2338097T3 (es) | 2010-05-04 |
Family
ID=22728668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01930480T Expired - Lifetime ES2338097T3 (es) | 2000-04-14 | 2001-04-11 | Procedimiento de identificacion selectiva. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20020098524A1 (enExample) |
| EP (1) | EP1360500B1 (enExample) |
| JP (2) | JP4966470B2 (enExample) |
| AT (1) | ATE455304T1 (enExample) |
| AU (1) | AU2001257012A1 (enExample) |
| CA (1) | CA2405715C (enExample) |
| CY (1) | CY1109876T1 (enExample) |
| DE (1) | DE60141088D1 (enExample) |
| DK (1) | DK1360500T3 (enExample) |
| ES (1) | ES2338097T3 (enExample) |
| PT (1) | PT1360500E (enExample) |
| WO (1) | WO2001079479A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1360500E (pt) | 2000-04-14 | 2010-04-19 | Genencor Int | Métodos para direccionamento selectivo |
| US7129326B2 (en) * | 2000-04-14 | 2006-10-31 | Genencor International, Inc. | Methods for selective targeting |
| AU2002230890A1 (en) * | 2000-12-14 | 2002-06-24 | Genencor International, Inc. | Targeted enzyme prodrug therapy |
| WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| EP2431048B1 (en) | 2002-10-08 | 2015-03-11 | Danisco US Inc. | Phenolic binding peptides |
| WO2004048399A2 (en) | 2002-11-25 | 2004-06-10 | Genencor International, Inc. | Skin or hair binding peptides |
| US20050226839A1 (en) * | 2003-09-08 | 2005-10-13 | Xueying Huang | Pepetide-based body surface reagents for personal care |
| US7285264B2 (en) * | 2003-09-08 | 2007-10-23 | E.I. Du Pont De Nemours And Company | Peptide-based body surface coloring reagents |
| US7220405B2 (en) | 2003-09-08 | 2007-05-22 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
| US7807141B2 (en) | 2003-09-08 | 2010-10-05 | E.I. Du Pont De Nemours And Company | Peptide-based oral care surface reagents for personal care |
| US20100311641A1 (en) * | 2003-09-08 | 2010-12-09 | E. I. Du Pont De Nemours And Company | Peptide-based body surface coloring reagents |
| US20050054752A1 (en) * | 2003-09-08 | 2005-03-10 | O'brien John P. | Peptide-based diblock and triblock dispersants and diblock polymers |
| US7585495B2 (en) | 2003-09-08 | 2009-09-08 | E. I. Du Pont De Nemours And Company | Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom |
| EP1663118A4 (en) * | 2003-09-08 | 2008-10-15 | Du Pont | HAIR CARE AND COLORANTS BASED ON PEPTIDES FOR HAIR, SKIN AND NAILS |
| DK1680507T3 (da) * | 2003-11-06 | 2011-10-10 | Danisco Us Inc | Bakterieekspression af proteaseinhibitorer og varianter deraf |
| US9062392B2 (en) * | 2003-12-30 | 2015-06-23 | Intel Corporation | Methods for isolating a peptide methods for identifying a peptide |
| US20070196305A1 (en) * | 2005-03-01 | 2007-08-23 | Hong Wang | Method for identifying hair conditioner-resistant hair-binding peptides and hair benefit agents therefrom |
| BRPI0613548A2 (pt) | 2005-05-05 | 2011-01-18 | Genencor Int | composições de cuidado pessoal e métodos para seu uso |
| US20060286047A1 (en) * | 2005-06-21 | 2006-12-21 | Lowe David J | Methods for determining the sequence of a peptide motif having affinity for a substrate |
| US20070065387A1 (en) * | 2005-09-16 | 2007-03-22 | Beck William A | Method for enhancing the effect of particulate benefit agents |
| US7736633B2 (en) | 2005-09-28 | 2010-06-15 | E.I. Du Pont De Nemours And Company | Method for enhancing effects of colorants and conditioners |
| US8318659B2 (en) | 2005-11-15 | 2012-11-27 | E I Du Pont De Nemours And Company | Peptide-based organic sunscreens |
| US7928076B2 (en) | 2005-12-15 | 2011-04-19 | E. I. Du Pont De Nemours And Company | Polypropylene binding peptides and methods of use |
| US7709601B2 (en) | 2005-12-15 | 2010-05-04 | E. I. Du Pont De Nemours And Company | Nylon binding peptides and methods of use |
| US7858581B2 (en) * | 2005-12-15 | 2010-12-28 | E. I. Du Pont De Nemours And Company | PMMA binding peptides and methods of use |
| US7906617B2 (en) | 2005-12-15 | 2011-03-15 | E. I. Du Pont De Nemours And Company | Polyethylene binding peptides and methods of use |
| US7700716B2 (en) | 2005-12-15 | 2010-04-20 | E. I. Du Pont De Nemours And Company | Polytetrafluoroethylene binding peptides and methods of use |
| US7632919B2 (en) * | 2005-12-15 | 2009-12-15 | E.I. Du Pont De Nemours And Company | Polystyrene binding peptides and methods of use |
| WO2007109299A2 (en) * | 2006-03-21 | 2007-09-27 | Duke University | Peptide |
| US7749957B2 (en) | 2006-04-06 | 2010-07-06 | E.I. Du Pont De Nemours And Company | Clay-binding peptides and methods of use |
| DE102006030028A1 (de) * | 2006-06-29 | 2008-02-14 | Forschungszentrum Jülich GmbH | Verfahren zum Auffinden von spezifisch an einen Köder bindende Moleküle, sowie spezifisch an einen Köder bindende Moleküle und deren Verwendung |
| US20080280810A1 (en) * | 2006-10-30 | 2008-11-13 | O'brien John P | Peptides having affinity for body surfaces |
| US20080175798A1 (en) * | 2006-12-11 | 2008-07-24 | Beck William A | Peptide-based hair protectants |
| US7951559B2 (en) | 2007-07-25 | 2011-05-31 | E.I. Du Pont De Nemours And Company | Recombinant peptide production using a cross-linkable solubility tag |
| US7678883B2 (en) | 2007-07-25 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Solubility tags for the expression and purification of bioactive peptides |
| US7829311B2 (en) | 2007-07-25 | 2010-11-09 | E.I. Du Pont De Nemours And Company | Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate |
| US7754680B2 (en) | 2007-07-26 | 2010-07-13 | E. I. Du Pont De Nemours And Company | Peptides for binding calcium carbonates and methods of use |
| US20090142283A1 (en) * | 2007-11-30 | 2009-06-04 | E. I. Du Pont De Nemours And Company | Peptide-based antidandruff reagents |
| US7998702B2 (en) * | 2008-09-17 | 2011-08-16 | E. I. Du Pont De Nemours And Company | Mutant arabinose promoter for inducible gene expression |
| US7772181B2 (en) * | 2008-10-15 | 2010-08-10 | Danisco Us Inc. | Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors |
| AU2008362898B2 (en) | 2008-10-15 | 2013-02-28 | Danisco Us Inc. | Modified variant Bowman Birk Protease inhibitors |
| US7803902B2 (en) | 2008-10-15 | 2010-09-28 | Danisco Us Inc. | Modified variant bowman birk protease inhibitors |
| US8697654B2 (en) | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
| US20100158837A1 (en) | 2008-12-18 | 2010-06-24 | E. I. Du Pont De Nemours And Company | Iron oxide-binding peptides |
| US7915011B2 (en) * | 2009-03-05 | 2011-03-29 | E.I. Du Pont De Nemours And Company | Host cell modifications that improve peptide production and downstream processing |
| BRPI1014677A2 (pt) * | 2009-03-30 | 2016-04-12 | Du Pont | sistemas baseados em peptídeos para distribuição de agentes cosméticos |
| US8481678B2 (en) | 2009-03-30 | 2013-07-09 | E I Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
| US20100310495A1 (en) * | 2009-06-08 | 2010-12-09 | E. I. Du Pont De Nemours And Company | Peptides having affinity for poly (benzyl methacrylate-co-methacrylic acid) potassium salt copolymers and methods of use |
| US20130224730A1 (en) * | 2009-11-18 | 2013-08-29 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Peptide ligands |
| US8609621B2 (en) | 2010-11-15 | 2013-12-17 | E I Du Pont De Nemours And Company | Acid-cleavable linkers exhibiting altered rates of acid hydrolysis |
| CN103261430A (zh) | 2010-12-20 | 2013-08-21 | 纳幕尔杜邦公司 | 靶向过水解酶 |
| ES2784495T3 (es) | 2010-12-20 | 2020-09-28 | Dupont Us Holding Llc | Generación enzimática de perácidos para su uso en productos para el cuidado bucodental |
| US9273336B2 (en) | 2011-02-21 | 2016-03-01 | E. I. Du Pont De Nemours And Company | Recombinant host cells having an increase in buoyant density |
| US9062312B2 (en) | 2011-06-21 | 2015-06-23 | Danisco Us Inc. | Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications |
| US20140323315A1 (en) | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| CN108473979B (zh) * | 2015-12-28 | 2022-08-19 | 出光兴产株式会社 | 肽标签及包含它的带有标签的蛋白质 |
| CN110453292B (zh) * | 2019-06-28 | 2021-06-29 | 浙江大学 | 一种利用噬菌体抗体库高效筛选纤维蛋白原的方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2437090A1 (de) | 1974-08-01 | 1976-02-19 | Hoechst Ag | Reinigungsmittel |
| US3929676A (en) * | 1974-08-02 | 1975-12-30 | Int Flavors & Fragrances Inc | Bicyclic fragrance materials and processes therefor |
| US4760025A (en) * | 1984-05-29 | 1988-07-26 | Genencor, Inc. | Modified enzymes and methods for making same |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800197A (en) * | 1987-07-17 | 1989-01-24 | Richardson-Vicks Inc. | Anti-acne composition |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5011681A (en) * | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
| US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| CA2084307A1 (en) | 1990-06-01 | 1991-12-02 | Cetus Oncology Corporation | Compositions and methods for identifying biologically active molecules |
| DE69128350T2 (de) * | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5292646A (en) * | 1991-02-06 | 1994-03-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| US5665539A (en) * | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5677136A (en) * | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US6341256B1 (en) * | 1995-03-31 | 2002-01-22 | Curagen Corporation | Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination |
| US5609826A (en) | 1995-04-17 | 1997-03-11 | Ontogen Corporation | Methods and apparatus for the generation of chemical libraries |
| US6475806B1 (en) | 1995-06-07 | 2002-11-05 | Praecis Pharmaceuticals, Inc. | Anchor libraries and identification of peptide binding sequences |
| ATE240347T1 (de) | 1995-12-18 | 2003-05-15 | Praecis Pharm Inc | Verfahren zum nachweis von verbindungen die bestimmte zielmoleküle binden |
| CA2249419A1 (en) | 1996-03-22 | 1997-09-25 | Ontogen Corporation | Methods for spatially-dispersed positionally-encoded combinatorial library synthesis |
| US6620587B1 (en) | 1997-05-28 | 2003-09-16 | Discerna Limited | Ribosome complexes as selection particles for in vitro display and evolution of proteins |
| GB9716094D0 (en) * | 1997-07-30 | 1997-10-01 | Univ Glasgow | Mehods for screening bacteriophage libraries |
| US6639051B2 (en) * | 1997-10-20 | 2003-10-28 | Curis, Inc. | Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| GB9805793D0 (en) * | 1998-03-18 | 1998-05-13 | Glaxo Group Ltd | Sodium ion channels |
| US6861227B2 (en) * | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| US6201104B1 (en) | 1998-12-04 | 2001-03-13 | Entremed, Inc. | Angiogenesis—inhibiting protein binding peptides and proteins and methods of use |
| PT1360500E (pt) | 2000-04-14 | 2010-04-19 | Genencor Int | Métodos para direccionamento selectivo |
-
2001
- 2001-04-11 PT PT01930480T patent/PT1360500E/pt unknown
- 2001-04-11 ES ES01930480T patent/ES2338097T3/es not_active Expired - Lifetime
- 2001-04-11 DK DK01930480.7T patent/DK1360500T3/da active
- 2001-04-11 EP EP01930480A patent/EP1360500B1/en not_active Expired - Lifetime
- 2001-04-11 CA CA2405715A patent/CA2405715C/en not_active Expired - Fee Related
- 2001-04-11 AT AT01930480T patent/ATE455304T1/de active
- 2001-04-11 WO PCT/US2001/011811 patent/WO2001079479A2/en not_active Ceased
- 2001-04-11 DE DE60141088T patent/DE60141088D1/de not_active Expired - Lifetime
- 2001-04-11 US US09/832,723 patent/US20020098524A1/en not_active Abandoned
- 2001-04-11 AU AU2001257012A patent/AU2001257012A1/en not_active Abandoned
- 2001-04-11 JP JP2001577462A patent/JP4966470B2/ja not_active Expired - Fee Related
-
2004
- 2004-10-19 US US10/968,732 patent/US20050112692A1/en not_active Abandoned
-
2008
- 2008-04-08 US US12/099,632 patent/US8318640B2/en not_active Expired - Lifetime
-
2010
- 2010-03-10 CY CY20101100233T patent/CY1109876T1/el unknown
-
2011
- 2011-07-27 JP JP2011164796A patent/JP5689764B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-23 US US13/658,713 patent/US8779091B2/en not_active Expired - Fee Related
-
2014
- 2014-05-29 US US14/289,799 patent/US20140342930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE455304T1 (de) | 2010-01-15 |
| CA2405715C (en) | 2011-11-15 |
| DK1360500T3 (da) | 2010-05-25 |
| JP4966470B2 (ja) | 2012-07-04 |
| CA2405715A1 (en) | 2001-10-25 |
| EP1360500A2 (en) | 2003-11-12 |
| WO2001079479A2 (en) | 2001-10-25 |
| CY1109876T1 (el) | 2014-09-10 |
| US20050112692A1 (en) | 2005-05-26 |
| WO2001079479A3 (en) | 2003-08-21 |
| US20020098524A1 (en) | 2002-07-25 |
| US20140342930A1 (en) | 2014-11-20 |
| DE60141088D1 (de) | 2010-03-04 |
| US20090093393A1 (en) | 2009-04-09 |
| JP5689764B2 (ja) | 2015-03-25 |
| PT1360500E (pt) | 2010-04-19 |
| US20130102757A1 (en) | 2013-04-25 |
| AU2001257012A1 (en) | 2001-10-30 |
| EP1360500B1 (en) | 2010-01-13 |
| US8779091B2 (en) | 2014-07-15 |
| US8318640B2 (en) | 2012-11-27 |
| JP2012002818A (ja) | 2012-01-05 |
| JP2004518403A (ja) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2338097T3 (es) | Procedimiento de identificacion selectiva. | |
| US9120840B2 (en) | Methods for selective targeting | |
| Sidhu et al. | [21] Phage display for selection of novel binding peptides | |
| Scott et al. | A family of concanavalin A-binding peptides from a hexapeptide epitope library. | |
| US5843701A (en) | Systematic polypeptide evolution by reverse translation | |
| CN102703453B (zh) | 特异性识别链霉素的dna适配体及其应用 | |
| JP2001521395A (ja) | 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法 | |
| JP2018154627A (ja) | スクリーニング方法およびその使用 | |
| US10351970B2 (en) | Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands | |
| Wang et al. | Highly paralleled emulsion droplets for efficient isolation, amplification, and screening of cancer biomarker binding phages | |
| CN102010865A (zh) | 一种特异识别单核细胞增生李斯特菌的核酸适配子及其筛选方法与应用 | |
| Anni et al. | Selection of phage-display library peptides recognizing ethanol targets on proteins | |
| Kitamura et al. | Development of systemic in vitro evolution and its application to generation of peptide-aptamer-based inhibitors of cathepsin E | |
| Messmer et al. | Sequential determination of ligands binding to discrete components in heterogeneous mixtures by iterative panning and blocking (IPAB) | |
| Vani et al. | A high throughput combinatorial library technique for identifying formalin-sensitive epitopes | |
| US20020038000A1 (en) | Systematic polypeptide evolution by reverse translation | |
| Farrera‐Soler et al. | Structure–Affinity Relationship Analysis and Affinity Maturation of a Calprotectin‐Binding Peptide | |
| Kundu et al. | Manipulation of unfolding-induced protein aggregation by peptides selected for aggregate-binding ability through phage display library screening | |
| Nygren | Affinity ligands from biological combinatorial libraries | |
| CN112526130A (zh) | 检测轮状病毒/诺如病毒的试剂盒及其应用 | |
| Chen et al. | Selection of substrate recognition sequence of protein kinase with ferric chelation affinity chromatography |